228 related articles for article (PubMed ID: 7684862)
1. Radionuclide-targeted therapy for the management of metastatic bone pain.
Ackery D; Yardley J
Semin Oncol; 1993 Jun; 20(3 Suppl 2):27-31. PubMed ID: 7684862
[TBL] [Abstract][Full Text] [Related]
2. Bone pain palliation with 85Sr therapy.
Giammarile F; Mognetti T; Blondet C; Desuzinges C; Chauvot P
J Nucl Med; 1999 Apr; 40(4):585-90. PubMed ID: 10210217
[TBL] [Abstract][Full Text] [Related]
3. Bone pain palliation with strontium-89 in cancer patients with bone metastases.
Giammarile F; Mognetti T; Resche I
Q J Nucl Med; 2001 Mar; 45(1):78-83. PubMed ID: 11456379
[TBL] [Abstract][Full Text] [Related]
4. [Strontium-89 for bone metastases from prostate cancer: an update].
Zhao WW; Xie P; Deng HF
Zhonghua Nan Ke Xue; 2010 Mar; 16(3):269-72. PubMed ID: 20369560
[TBL] [Abstract][Full Text] [Related]
5. Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma.
Breen SL; Powe JE; Porter AT
J Nucl Med; 1992 Jul; 33(7):1316-23. PubMed ID: 1613572
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic efficacy of strontium-89-chloride for bone metastatic tumors without bone pain].
Ouyang W; Liu JH; Liu WY
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar; 27(3):390-1. PubMed ID: 17426002
[TBL] [Abstract][Full Text] [Related]
7. Palliation of bone pain in patients with metastatic cancer using strontium-89 (Metastron).
Kan MK
Cancer Nurs; 1995 Aug; 18(4):286-91. PubMed ID: 7545083
[TBL] [Abstract][Full Text] [Related]
8. Strontium-89 therapy for painful osseous metastatic prostate and breast cancer.
Hansen DV; Holmes ER; Catton G; Thorne DA; Chadwick DH; Schmutz DA
Am Fam Physician; 1993 Jun; 47(8):1795-800. PubMed ID: 7684554
[TBL] [Abstract][Full Text] [Related]
9. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
Sciuto R; Festa A; Rea S; Pasqualoni R; Bergomi S; Petrilli G; Maini CL
J Nucl Med; 2002 Jan; 43(1):79-86. PubMed ID: 11801708
[TBL] [Abstract][Full Text] [Related]
10. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases.
Nair N
J Nucl Med; 1999 Feb; 40(2):256-61. PubMed ID: 10025832
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with strontium-89 in prostatic and breast cancer patients.
Robinson RG; Preston DF; Baxter KG; Dusing RW; Spicer JA
Semin Oncol; 1993 Jun; 20(3 Suppl 2):44-8. PubMed ID: 8503027
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of strontium-89 palliative therapy in patients with painful bone metastases.
Zorga P; Birkenfeld B; Listewnik MH; Piwowarska-Bilska H
Ann Acad Med Stetin; 2011; 57(1):49-53; discussion 53. PubMed ID: 22593991
[TBL] [Abstract][Full Text] [Related]
13. Decreased serum E-selectin concentration after 89Sr-chloride therapy for metastatic prostate cancer bone pain.
Papatheofanis FJ
J Nucl Med; 2000 Jun; 41(6):1021-4. PubMed ID: 10855628
[TBL] [Abstract][Full Text] [Related]
14. [The efficacy of therapy using 89Sr-strontium chloride in 200 patients with bone metastases of a prostatic cancer].
Haesner M; Buchali K; Pink V; Lips H
Nuklearmedizin; 1992 Mar; 31(2):48-52. PubMed ID: 1373485
[TBL] [Abstract][Full Text] [Related]
15. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
Papatheofanis FJ
J Nucl Med; 1997 Aug; 38(8):1175-9. PubMed ID: 9255144
[TBL] [Abstract][Full Text] [Related]
16. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy.
Tu SM; Kim J; Pagliaro LC; Vakar-Lopez F; Wong FC; Wen S; General R; Podoloff DA; Lin SH; Logothetis CJ
J Clin Oncol; 2005 Nov; 23(31):7904-10. PubMed ID: 16258090
[TBL] [Abstract][Full Text] [Related]
17. Systemic radionuclide therapy of bone metastases with strontium-89.
Porter AT; Davis LP
Oncology (Williston Park); 1994 Feb; 8(2):93-6; discussion 96, 99-101. PubMed ID: 8167090
[TBL] [Abstract][Full Text] [Related]
18. Radionuclide therapy for painful bone metastases. An Italian multicentre observational study. Writing Committee of an Ad Hoc Study Group.
Piffanelli A; Dafermou A; Giganti M; Colamussi P; Pizzocaro C; Bestagno M;
Q J Nucl Med; 2001 Mar; 45(1):100-7. PubMed ID: 11456368
[TBL] [Abstract][Full Text] [Related]
19. Strontium-89 therapy for the pain of osseous metastases.
Silberstein EB; Williams C
J Nucl Med; 1985 Apr; 26(4):345-8. PubMed ID: 3920361
[TBL] [Abstract][Full Text] [Related]
20. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial.
Porter AT; McEwan AJ
Semin Oncol; 1993 Jun; 20(3 Suppl 2):38-43. PubMed ID: 7684865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
